Association of adverse events (AES) with efficacy outcomes for cabozantinib (C) in patients (PTS) with advanced hepatocellular carcinoma (AHCC) in the phase 3 CELESTIAL trial Meeting Abstract
| Authors: | Waidmann, O.; Abou-Alfa, G. K.; Meker, T.; Cheng, A. L.; Cicin, I.; Bolondi, L.; Klumpem, H. J.; Chan, S. L.; Dadduzio, V.; Milwee, S.; Dubey, S.; Kelley, R. K.; El-Khoueiry, A. B. |
| Abstract Title: | Association of adverse events (AES) with efficacy outcomes for cabozantinib (C) in patients (PTS) with advanced hepatocellular carcinoma (AHCC) in the phase 3 CELESTIAL trial |
| Meeting Title: | 34. Deutscher Krebskongress (DKK) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 43 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Feb 19-22 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2020-02-01 |
| Start Page: | 60 |
| Language: | English |
| ACCESSION: | WOS:000517158700149 |
| PROVIDER: | wos |
| DOI: | 10.1159/000506491 |
| Notes: | "34th German Cancer Congress" -- Meeting Abstract: 171 -- Source: Wos |
